Delay in B-lymphocyte recovery and function following rituximab for EBV-associated lymphoproliferative disease early post-allogeneic hematopoietic SCT
Authors:
Open Access
- 24 November 2008
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 43 (9) , 679-684
Abstract
Treatment with rituximab is highly effective for EBV-associated post transplant lymphoproliferative disease. However, little is known about its immunological sequelae in pediatric allogeneic hematopoietic SCT (HSCT). Time to normal CD19+ B-lymphocyte values in blood and intravenous immunoglobulin (IVIG) substitution needed to maintain an IgG>400 mg per 100 ml in six consecutive pediatric allogeneic HSCT patients treated with rituximab for symptomatic EBV reactivation were compared with a matched cohort of non-rituximab-treated patients. Follow-up of the six patients ranged from 149 to 1546 days; all but one survived. The mean (±s.d.) time to recovery of CD19+ B-lymphocytes was 353±142 days as compared with 139±42 in the controls (PP3 years and ultimately required two stem cell boosts. Rituximab is a live-saving treatment for pediatric HSCT patients but may lead to prolonged and even persistent B-cell deficiency.Keywords
This publication has 34 references indexed in Scilit:
- Septic polyarthritis with Ureaplasma urealyticum in a patient with prolonged agammaglobulinemia and B-cell aplasia after allogeneic HSCT and rituximab pretreatmentBone Marrow Transplantation, 2007
- Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non‐Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantationBritish Journal of Haematology, 2007
- Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphomaBone Marrow Transplantation, 2006
- Management of patients with post-transplant lymphoproliferative disorder: the role of rituximabTransplant International, 2006
- Single agent efficacy of rituximab in childhood immunosuppression related lymphoproliferative disease: a United Kingdom Children's Cancer Study Group (UKCCSG) retrospective reviewLeukemia & Lymphoma, 2006
- Post-Transplant Lymphoproliferative Disorder in ChildrenPediatric Drugs, 2005
- Impaired recovery of Epstein-Barr virus (EBV)—specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative diseaseBlood, 2003
- Immunophenotyping of blood lymphocytes in childhoodReference values for lymphocyte subpopulationsThe Journal of Pediatrics, 1997
- CD20: a regulator of cell-cycle progression of B lymphocytesImmunology Today, 1994
- Fatal Aplastic Anemia Caused by Epstein-Barr Virus Infection after Autologous Bone Marrow Transplantation for Non-Hodgkin Malignant Lymphoma.Internal Medicine, 1994